Skip to content
DataLookout
Menu

SemenGlutideNCT07946796

Semaglutide Effects on Sperm Concentration in Overweight Infertile Men

StatusNot Yet Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Difference in sperm concentration or total sperm count on day 200
Timeframe: From baseline to day 200

Secondary (19)

Difference in sperm concentration from baseline to day 300
Differences and changes in DNA fragmentation index (%) from baseline to day 300
Changes in sperm parameters from baseline to day 300
Differences in sperm production from baseline to day 300
Differences in body mass index (BMI) from baseline to day 300
Show 14 moreShow less
Differences in total body fat percentage (%) from baseline to day 300
Differences in bone mineral density (BMD) g/cm^2 from baseline to day 300
Changes in subjective symptoms of androgen deficiency from baseline to day 300
Changes in male sexual function from baseline to day 300
Changes in total testosterone (nmol/L) and free testosterone (nmol/L) from baseline to day 300
Differences in luteinizing hormone (IU/L) and follicel stimulating hormone (IU/L) from baseline to day 300
Differences in HbA1c from baseline to day 300
Differences in lipid profile from baseline to day 300
Differences in total muscle mass (kg) from baseline to day 300
Differences in trabecular bone score (TBS) from baseline to day 300
Differences in sex hormone binding globulin (SHBG) (nmol/L) from baseline to day 300
Differences in Anti-Müllerian Hormone (AMH) (pmol/L) from baseline to day 300
Differences in inhibin B (ng/L) from baseline to day 300
Differences in HOMA-IR from baseline to day 300

Arms and interventions

SemaglutideActive comparator

Semaglutide 2.4 mg administered subcutaneously once weekly

PlaceboPlacebo comparator

Saline administered subcutaneously once weekly

Drugs: Semaglutide (Wegovy®), Placebo (saline)

Sites

1 site in 1 country

  • Division of Translational Endocrinology, Department of Endocrinology and Internal Medicine, Copenhagen University Hospital Herlev.Herlev, Denmark